Introduction
Actinium-225 PSMA therapy (Ac-225 PSMA) is an advanced targeted radionuclide treatment used for selected patients with advanced prostate cancer.
It is a form of alpha-particle radioligand therapy, designed to deliver highly potent, short-range radiation directly to prostate cancer cells while minimizing exposure to surrounding healthy tissue.
This therapy targets prostate-specific membrane antigen (PSMA), a protein strongly expressed on prostate cancer cells, particularly in advanced and treatment-resistant disease.
Actinium-225 emits alpha particles with very high energy and limited penetration, allowing precise destruction of cancer cells at the microscopic level.
Türkiye is a trusted destination for advanced nuclear medicine therapies, offering experienced specialists, modern treatment facilities, and integrated prostate cancer care.
Averia Health supports international patients through ethical, structured, and fully coordinated Actinium-225 PSMA therapy focused on safety, precision, and continuity of care.
Why Choose Türkiye for Actinium-225 PSMA Therapy
Türkiye is internationally recognized for advanced prostate cancer treatment because of:
- Experienced nuclear medicine physicians and oncologists
- Availability of alpha-particle radioligand therapy in specialized centers
- Advanced nuclear medicine treatment units
- Multidisciplinary prostate cancer care teams
- Strict radiation safety and quality assurance protocols
- Internationally accredited hospitals
Türkiye combines cutting-edge targeted therapy with comprehensive oncologic expertise.
Why Choose Averia Health
Averia Health provides structured coordination for Actinium-225 PSMA therapy:
- Pre-arrival review of medical history, pathology, and prior treatments
- Coordination of PSMA PET-CT eligibility assessment
- Referral to experienced nuclear medicine therapy centers
- Multidisciplinary coordination (urology, medical oncology, nuclear medicine)
- Clear explanation of treatment goals, benefits, and limitations
- Professional interpreter services
- 24/7 patient support during your stay
- Post-therapy follow-up and international care coordination
Our approach prioritizes ethical practice, patient safety, and informed decision-making.
Who Is a Candidate for Actinium-225 PSMA Therapy
Actinium-225 PSMA therapy may be considered for patients with:
- Advanced or metastatic prostate cancer
- Castration-resistant prostate cancer (CRPC)
- PSMA-positive disease confirmed on PSMA PET-CT
- Disease progression despite standard therapies, including Lu-177 PSMA in some cases
- Adequate bone marrow, kidney, and liver function
Final eligibility is determined after comprehensive specialist evaluation.
Diagnostic Evaluation Before Therapy
Before treatment, patients typically undergo:
- PSMA PET-CT scan to confirm PSMA expression
- Blood tests to assess bone marrow, kidney, and liver function
- Review of prior prostate cancer treatments and response
- Oncology and nuclear medicine consultation
- Overall health and suitability assessment
Accurate patient selection is essential for safety and therapeutic benefit.
Actinium-225 PSMA Therapy Procedure
Radioligand Administration
Actinium-225 PSMA is administered intravenously under controlled conditions.
Alpha-Particle Targeted Therapy
The radioligand binds to PSMA-expressing cancer cells and delivers high-energy alpha radiation that damages cancer cell DNA.
Post-Treatment Monitoring
Patients are monitored for side effects and radiation safety compliance.
The procedure is performed by experienced nuclear medicine teams following strict international safety standards.
Treatment Journey in Türkiye
- Pre-Arrival Case Review
Medical records, imaging, and laboratory results are evaluated. - Eligibility Confirmation
PSMA PET-CT and clinical criteria confirm suitability. - Personalized Treatment Planning
Therapy approach, expectations, and precautions are explained clearly. - Actinium-225 PSMA Therapy
Treatment is administered in a specialized nuclear medicine unit. - Post-Therapy Care & Monitoring
Side effects and laboratory values are monitored closely. - Follow-Up & Oncologic Continuity
Ongoing care and international follow-up are coordinated.
Expected Results & Benefits
- Highly targeted treatment of PSMA-positive prostate cancer
- Potential disease control in advanced or treatment-resistant cases
- Reduction in tumor activity at the cellular level
- Treatment option when conventional therapies are limited
- Precision targeting with minimal radiation to surrounding tissue
Response varies depending on disease extent and prior treatments.
Risks & Considerations
Actinium-225 PSMA therapy is a potent treatment and may involve:
- Dry mouth (xerostomia) due to salivary gland uptake
- Fatigue
- Temporary bone marrow suppression
- Nausea or mild discomfort
- Need for careful dosing and monitoring
All potential risks are explained thoroughly before treatment.
What’s Included in Your Medical Trip
- Pre-therapy consultations and eligibility evaluation
- PSMA PET-CT coordination (if required)
- Actinium-225 PSMA therapy
- Nuclear medicine and hospital services
- Post-therapy monitoring and supportive care
- Interpreter services
- 24/7 patient support
- International oncology follow-up coordination
Averia Health ensures ethical, precise, and patient-centered alpha-radioligand therapy care.
Frequently Asked Questions
How is Actinium-225 PSMA different from Lutetium-177 PSMA?
Actinium-225 delivers alpha radiation, which is more potent and shorter-range than beta radiation from Lutetium-177.
Is Actinium-225 PSMA therapy chemotherapy?
No. It is a targeted alpha-radioligand therapy, not chemotherapy.
Who is this treatment best suited for?
Patients with advanced, PSMA-positive prostate cancer, often after other treatments.
Is the treatment safe?
Yes, when performed in specialized centers with careful monitoring.
Can follow-up care continue after returning home?
Yes. International follow-up and coordination are provided.
Ready to Start Your Health Journey?
Access next-generation targeted prostate cancer treatment with Actinium-225 PSMA therapy in Türkiye.
Request a free quote or contact us on WhatsApp to speak with our oncology coordination team.
